Scilex (SCLX) said Wednesday it has concluded its phase 2 meeting with the US Food and Drug Administration regarding its product candidate SP-103, which is intended for treating neck pain with muscle spasms.
The FDA outlined a clear pathway to a new drug application following the completion of phase 3 trials, the company said.
Shares of Scilex were up 1.5% in recent Wednesday trading.
Price: 1.01, Change: +0.02, Percent Change: +1.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.